BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension

Reuters03-31

BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension

BridgeBio published medical research presentation on long-term outcomes from ATTRibute-CM open-label extension evaluating acoramidis in transthyretin amyloid cardiomyopathy through Month 54.
Continuous acoramidis cut risk of all-cause mortality composite by 45% vs placebo through Month 54; hazard ratio 0.55 (95% CI 0.42-0.74).
Continuous acoramidis reduced risk of cardiovascular-related mortality by 49% vs placebo through Month 54; hazard ratio 0.51 (95% CI 0.36-0.71).
Data showed NT-proBNP stabilized with continuous acoramidis through Month 54.
Safety results showed treatment-emergent serious adverse events in 47.9% of continuous acoramidis group during Month 30-54 open-label period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623531326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 03:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623531326","market":"nz","top_or_hot":-1,"title":"BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          BridgeBio published medical research presentation on long-term outcomes from ATTRibute-CM open-label extension evaluating acoramidis in transthyretin amyloid cardiomyopathy through Month 54.\n        </li>\n<li>\n          Continuous acoramidis cut risk of all-cause mortality composite by 45% vs placebo through Month 54; hazard ratio 0.55 (95% CI 0.42-0.74).\n        </li>\n<li>\n          Continuous acoramidis reduced risk of cardiovascular-related mortality by 49% vs placebo through Month 54; hazard ratio 0.51 (95% CI 0.36-0.71).\n        </li>\n<li>\n          Data showed NT-proBNP stabilized with continuous acoramidis through Month 54.\n        </li>\n<li>\n          Safety results showed treatment-emergent serious adverse events in 47.9% of continuous acoramidis group during Month 30-54 open-label period.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 03:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          BridgeBio published medical research presentation on long-term outcomes from ATTRibute-CM open-label extension evaluating acoramidis in transthyretin amyloid cardiomyopathy through Month 54.\n        </li>\n<li>\n          Continuous acoramidis cut risk of all-cause mortality composite by 45% vs placebo through Month 54; hazard ratio 0.55 (95% CI 0.42-0.74).\n        </li>\n<li>\n          Continuous acoramidis reduced risk of cardiovascular-related mortality by 49% vs placebo through Month 54; hazard ratio 0.51 (95% CI 0.36-0.71).\n        </li>\n<li>\n          Data showed NT-proBNP stabilized with continuous acoramidis through Month 54.\n        </li>\n<li>\n          Safety results showed treatment-emergent serious adverse events in 47.9% of continuous acoramidis group during Month 30-54 open-label period.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL5DdTC0:1","article_id":"2623531326","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623531326","pubTimestamp":1774900136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio published medical research presentation on long-term outcomes from ATTRibute-CM open-label extension evaluating acoramidis in transthyretin amyloid cardiomyopathy through Month 54.Continuous acoramidis cut risk of all-cause mortality composite by 45% vs placebo through Month 54; hazard ratio 0.55 .Continuous acoramidis reduced risk of cardiovascular-related mortality by 49% vs placebo through Month 54; hazard ratio 0.51 .Data showed NT-proBNP stabilized with continuous acoramidis through Month 54.Safety results showed treatment-emergent serious adverse events in 47.9% of continuous acoramidis group during Month 30-54 open-label period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4588":"碎股","BBIO":"BridgeBio Pharma, Inc.","BK4585":"ETF&股票定投概念"},"translate_title":"BridgeBio演示显示acoramidis在ATTR-CM试验扩展中将全因死亡风险降低45%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension\n    \n\n\n          BridgeBio published medical research presentation on long-term outcomes from ATTRibute-CM open-label extension evaluating acoramidis in transthyretin amyloid cardiomyopathy through Month 54.\n        \n\n          Continuous acoramidis cut risk of all-cause mortality composite by 45% vs placebo through Month 54; hazard ratio 0.55 (95% CI 0.42-0.74).\n        \n\n          Continuous acoramidis reduced risk of cardiovascular-related mortality by 49% vs placebo through Month 54; hazard ratio 0.51 (95% CI 0.36-0.71).\n        \n\n          Data showed NT-proBNP stabilized with continuous acoramidis through Month 54.\n        \n\n          Safety results showed treatment-emergent serious adverse events in 47.9% of continuous acoramidis group during Month 30-54 open-label period.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623531326","isCrawlerRequest":true}